Pharmaceutical

Biogen completes $1.15bn HI-Bio acquisition to expand immunology presence

The takeover, which includes the candidate felzartamab, for immune-mediated diseases, diversifies Biogen’s scope.

Jul 4, 2024 - 04:00
Biogen completes $1.15bn HI-Bio acquisition to expand immunology presence
The takeover, which includes the candidate felzartamab, for immune-mediated diseases, diversifies Biogen’s scope.
Read the original article

Tags:

Previous Article

Beacon secures $170m to advance ophthalmic gene therapies

Next Article

Emergent scores US medical countermeasure contracts worth over $250m

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Healthcare Payers for the Pharmaceutical Industry

Healthcare Payers for the Pharmaceutical Industry

Oct 4, 2024

STAT+: AI health care companies say they’ll keep humans in the loop. But what does that actually mean?

STAT+: AI health care companies say they’ll keep humans...

Mar 13, 2024

STAT+: Sen. Bernie Sanders publicly pressures Merck, J&J, and Bristol Myers Squibb to testify on drug pricing

STAT+: Sen. Bernie Sanders publicly pressures Merck, J&...

Nov 21, 2023